Investors of Replimune Group May Lead Securities Class Action Against Company

Legal Action Alert: Replimune Group Securities Lawsuit

Investors in Replimune Group, Inc. (NASDAQ: REPL) have an opportunity to take the lead in a securities class action lawsuit, first initiated by the Rosen Law Firm. This news comes as an essential reminder for those who purchased securities of Replimune between November 22, 2024, and July 21, 2025. The deadline to act as a lead plaintiff is approaching on September 22, 2025.

Background on the Lawsuit

Rosen Law Firm, renowned for advocating investors' rights, is encouraging those who may be affected to join the ongoing class action. The opportunity allows individuals to seek compensation without paying any upfront costs, relying on a contingency fee arrangement.

The lawsuit centers around allegations that Replimune's management made materially false or misleading statements regarding the prospects of its IGNYTE clinical trial. The FDA deemed this trial inadequate and poorly controlled, which raised significant concerns about the disclosures made to investors. Consequently, when the details of these inaccuracies became public, investors reportedly suffered financial damages.

How to Participate

If you purchased Replimune securities during the indicated class period and are interested in joining the lawsuit, you have the option to submit information through the Rosen Law Firm’s website at rosenlegal.com. Alternatively, you may directly contact Phillip Kim, Esq., toll-free at 866-767-3653, or email him at [email protected] For those wanting to fulfill the lead plaintiff role, it's crucial to act before the September deadline.

About the Rosen Law Firm

When selecting legal counsel, Rosen Law Firm emphasizes the importance of choosing a firm with proven success in leadership roles within securities class actions. Unlike many firms issuing similar notices that often do not litigate securities actions directly, Rosen has a solid track record, including a record settlement against a Chinese company, and has ranked at the forefront of securities class action settlements year after year.

The firm has successfully recovered significant financial compensation for investors, with over $438 million secured in 2019 alone. Founding partner Laurence Rosen received accolades from Law360 as a leading figure in the plaintiffs' bar, further solidifying the firm’s reputation as a reliable advocate for investors.

Conclusion

For those who invested in Replimune Group, this lawsuit represents a pivotal chance to assert your rights and potentially recover losses incurred during the class period. Ensure that you stay informed and consider joining the class action. Remember, no class has been certified yet, so individuals have the choice to select their legal representatives or to remain inactive at this stage, which will not affect their ability to reclaim any future recoveries.

Stay updated with the latest information by following the Rosen Law Firm on platforms such as Twitter and LinkedIn. Investors must act swiftly, as September 22, 2025, swiftly approaches.

For further details, you can reach out to the Rosen Law Firm at their headquarters located at 275 Madison Avenue, 40th Floor, New York, NY 10016, or via telephone at (212) 686-1060 or the toll-free line at (866) 767-3653.